Table 5 Univariate analyses of progression-free survival and overall survival based on continuous log₂ fold change in biomarkers at week 4

CA9

1.00 (0.92, 1.08)

1.04 (0.95, 1.14)

0.48

0.92 (0.84, 1.00)

0.93 (0.83, 1.03)

0.86

HGF

0.77 (0.63, 0.93)*

1.06 (0.88, 1.28)

0.02*

0. 80 (0.65, 0.98)*

1.00 (0.80, 1.26)

0.14

MET

1.16 (0.74, 1.83)

0.70 (0.41, 1.19)

0.13

1.02 (0.62, 1.67)

0.79 (0.43, 1.42)

0.52

GAS6

0.87 (0.60, 1.28)

0.88 (0.61, 1.29)

0.92

0.67 (0.44, 1.01)

1.05 (0.68, 1.60)

0.13

AXL

0.67 (0.41, 1.11)

0.88 (0.54, 1.44)

0.53

0.70 (0.41, 1.19)

0.86 (0.51, 1.47)

0.55

VEGF

0.95 (0.89, 1.01)

1.03 (0.95, 1.11)

0.13

0.90 (0.84, 0.97)*

0.92 (0.85, 1.01)

0.63

VEGFR2

1.05 (0.69, 1.60)

0.86 (0.54, 1.34)

0.52

1.06 (0.70, 1.61)

0.86 (0.53, 1.42)

0.48

IL-8

0.93 (0.85, 1.01)

1.00 (0.92, 1.09)

0.26

0.91 (0.83, 1.00)*

0.96 (0.88, 1.06)

0.37